Table 2 . Comparison the characteristics between and within study participants .
| Variable | TA group (n= 38) | PG group (n=38) | ***p | ||||
|
Before treatment mean (SD) |
After treatment mean (SD) |
Mean difference |
Before treatment mean (SD) |
After treatment mean (SD) |
Mean difference |
||
| Duration of bleeding (days) | 8.0 (1.82) | 6.65 (1.37)* | 1.31 | 8.0 (1.39) | 6.5(1.35)** | 1.5 | 0.99 |
| (PBAC) score | 304.4 (192.71) | 143.13(96.00)*# | 161.31 | 304.9(176.11) | 164.0(100.21)**# | 140.31 | 0.30 |
| Hemoglobin g/dL | 11.5 (0.86) | 12.7 (0.88)*© | 1.19 | 12.6 (0.86) | 13.0 (0.83)**© | 0.96 | 0.09 |
| Hematocrite (%) | 36.7(4.86) | 40.9 (4.19)*© | 4.27 | 37.8(4.45) | 42.9(5.1)**© | 5.01 | 0.60 |
| Ferritin ng/dL | 9.4 (5.84) | 16.4 (6.79)*# | 7.01 | 12.1 (10.79) | 23.5 (13.5)**# | 11.37 | 0.26 |
# Wilcoxon signed ranks test, © Paired t-test
* p< 0.001 compared with TA before treatment.
** p< 0.001 compared with PG group before treatment
***p after treatment comparison of TA and PG groups (t-test, Mann–Whitney test)